These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21406434)

  • 1. Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers.
    Ashby J; Garvey L; Erlwein OW; Lamba H; Weston R; Legg K; Latch N; McClure MO; Dickinson L; D'Avolio A; Back D; Winston A
    J Antimicrob Chemother; 2011 Jun; 66(6):1340-5. PubMed ID: 21406434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.
    Jackson A; D'Avolio A; Watson V; Bonora S; Back D; Taylor J; Armenis K; Gazzard B; Moyle G; Boffito M
    J Antimicrob Chemother; 2011 Apr; 66(4):885-9. PubMed ID: 21393207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers.
    Mora-Peris B; Else L; Goldmeier D; Mears A; Weston R; Cooke G; Khoo S; Back D; Winston A
    J Antimicrob Chemother; 2015; 70(6):1812-5. PubMed ID: 25693997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
    de Kanter CT; Blonk MI; Colbers AP; Schouwenberg BJ; Burger DM
    Clin Infect Dis; 2013 Jan; 56(2):300-6. PubMed ID: 23001704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir.
    Reynolds HE; Chrdle A; Egan D; Chaponda M; Else L; Chiong J; Back DJ; Khoo SH
    J Antimicrob Chemother; 2015 Feb; 70(2):550-4. PubMed ID: 25261424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
    Iwamoto M; Wenning LA; Petry AS; Laethem M; De Smet M; Kost JT; Breidinger SA; Mangin EC; Azrolan N; Greenberg HE; Haazen W; Stone JA; Gottesdiener KM; Wagner JA
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4338-43. PubMed ID: 18838589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Drug-Drug Interaction Study Between Raltegravir and Atorvastatin 20 mg in Healthy Volunteers.
    Blonk M; van Beek M; Colbers A; Schouwenberg B; Burger D
    J Acquir Immune Defic Syndr; 2015 May; 69(1):44-51. PubMed ID: 25942458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of raltegravir on the glucuronidation of lamotrigine.
    van Luin M; Colbers A; Verwey-van Wissen CP; van Ewijk-Beneken-Kolmer EW; van der Kolk M; Hoitsma A; da Silva HG; Burger DM
    J Clin Pharmacol; 2009 Oct; 49(10):1220-7. PubMed ID: 19717722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz does not meaningfully affect the single dose pharmacokinetics of 1200 mg raltegravir.
    Krishna R; East L; Larson P; Siringhaus T; Herpok L; Bethel-Brown C; Manthos H; Brejda J; Gartner M
    Biopharm Drug Dispos; 2016 Dec; 37(9):542-549. PubMed ID: 27704562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.
    Douglas Bruce R; Moody DE; Chodkowski D; Andrews L; Fang WB; Morrison J; Parsons TL; Friedland GH
    Am J Drug Alcohol Abuse; 2013 Mar; 39(2):80-5. PubMed ID: 23421567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteers.
    Blonk M; Colbers A; Poirters A; Schouwenberg B; Burger D
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5070-5. PubMed ID: 22802250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.
    Ramanathan S; Cheng A; Mittan A; Ebrahimi R; Kearney BP
    J Clin Pharmacol; 2006 May; 46(5):559-66. PubMed ID: 16638739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment.
    Gupta SK; Kantesaria B; Glue P
    Drug Discov Ther; 2013 Aug; 7(4):158-63. PubMed ID: 24071578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.
    Brainard DM; Kassahun K; Wenning LA; Petry AS; Liu C; Lunceford J; Hariparsad N; Eisenhandler R; Norcross A; DeNoia EP; Stone JA; Wagner JA; Iwamoto M
    J Clin Pharmacol; 2011 Jun; 51(6):943-50. PubMed ID: 20852006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
    Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
    Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
    Andrews E; Glue P; Fang J; Crownover P; Tressler R; Damle B
    Br J Clin Pharmacol; 2010 Jan; 69(1):51-7. PubMed ID: 20078612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting intestinal absorption of raltegravir using a population-based ADME simulation.
    Moss DM; Siccardi M; Back DJ; Owen A
    J Antimicrob Chemother; 2013 Jul; 68(7):1627-34. PubMed ID: 23515248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.